Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Announces Positive CATALYST Trial Results in Hypercortisolism and Diabetes
Details : Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Product Name : Korlym
Product Type : Steroid
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Poxel
Deal Size : Inapplicable
Deal Type : Inapplicable
Sumitomo And Poxel Announce TWYMEEG® Study Results For Type 2 Diabetes Treatment
Details : TWYMEEG (imeglimin hydrochloride), enhances insulin action by inhibiting hepatic glucose output and improving insulin signalling in both liver and skeletal muscle, in type 2 diabetes patients.
Product Name : Twymeeg
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Poxel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Details : Korlym (mifepristone) is an approved selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated in phase 4 for cushing syndrome.
Product Name : Korlym
Product Type : Steroid
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Details : Korlym (mifepristone) blocks cortisol receptors to manage hyperglycemia in adults with Cushing's syndrome who have type 2 diabetes or glucose intolerance.
Product Name : Korlym
Product Type : Steroid
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Details : Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Product Name : Korlym
Product Type : Steroid
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Mifepristone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Technosphere Insulin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Afrezza (human insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist and works as starts lowering blood sugars in ~12 minutes for adults living with type 1 or type 2 diabetes.
Product Name : Afrezza
Product Type : Hormone
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Technosphere Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Technosphere Insulin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, which is investigated in combination with insulin degludec for the treatment of type 1 diabetes.
Product Name : Afrezza
Product Type : Hormone
Upfront Cash : Inapplicable
June 11, 2023
Lead Product(s) : Technosphere Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JATENZO (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions, for the treatment of adult hypogonadal men with chronic kid...
Product Name : Jatenzo
Product Type : Hormone
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable